Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
11%
Ph phase_4
7
78%
Ph phase_2
1
11%

Phase Distribution

0

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
7(77.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Other(3)

Detailed Status

Completed5
unknown3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (11.1%)
Phase 31 (11.1%)
Phase 47 (77.8%)

Trials by Status

unknown333%
completed556%
not_yet_recruiting111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_4

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
completedphase_3

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

NCT03969953
not_yet_recruitingphase_4

Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke

NCT06396858
completedphase_4

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

NCT04853719
completedphase_2

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

NCT04273516
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05009862Phase 4

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

Completed
NCT03969953Phase 3

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

Completed
NCT06396858Phase 4

Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke

Not Yet Recruiting
NCT04853719Phase 4

Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients

Completed
NCT04273516Phase 2

Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

Completed
NCT05573958Phase 4

To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome

Unknown
NCT05210725Phase 4

Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease

Unknown
NCT04218656Phase 4

DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease

Completed
NCT04059679Phase 4

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9